Design Controls for the Medical Device IndustryThis reference provides real-world examples, strategies, and templates for the implementation of effective design control programs that meet current ISO 9000 and FDA QSR standards and regulations-offering product development models for the production of safe, durable, and cost-efficient medical devices and systems. Details procedures utilize |
No grāmatas satura
1.5. rezultāts no 5.
6. lappuse
Atvainojiet, šīs lappuses saturs ir ierobežots..
Atvainojiet, šīs lappuses saturs ir ierobežots..
50. lappuse
Atvainojiet, šīs lappuses saturs ir ierobežots..
Atvainojiet, šīs lappuses saturs ir ierobežots..
51. lappuse
Atvainojiet, šīs lappuses saturs ir ierobežots..
Atvainojiet, šīs lappuses saturs ir ierobežots..
69. lappuse
Atvainojiet, šīs lappuses saturs ir ierobežots..
Atvainojiet, šīs lappuses saturs ir ierobežots..
237. lappuse
Atvainojiet, šīs lappuses saturs ir ierobežots..
Atvainojiet, šīs lappuses saturs ir ierobežots..
Lietotāju komentāri - Rakstīt atsauksmi
Ierastajās vietās neesam atraduši nevienu atsauksmi.
Saturs
Overview AN IDEA IS BORN | 1 |
ASK THE CUSTOMER | 2 |
DESIGN CONTROLS AND THE FDA | 3 |
DESIGN CONTROLS AND REALITY | 4 |
DESIGN CONTROLS AND THE BOTTOM LINE | 5 |
DESIGN CONTROLS AND THE CUSTOMER | 7 |
Design and Development Planning | 11 |
WHATS A PLAN? | 13 |
Design Validation | 89 |
THE FDA AND VALIDATION | 90 |
TYPICAL VALIDATION ACTIVITIES | 92 |
COMMON RISK ANALYSIS TOOLS | 93 |
RISK ASSESSMENT OF MEDICAL DEVICE MATERIALS | 99 |
BIOCOMPATIBILITY | 102 |
REGULATORY ASPECTS OF BIOCOMPATIBILITY | 104 |
PHASES OF BIOCOMPATIBILITY TESTING | 107 |
THE FDA DESIGN CONTROLS AND PLANS | 14 |
PLANNING TECHNIQUES | 16 |
ARE PROJECTS REALLY ALWAYS LATE AND OVERBUDGET? | 19 |
Design Input I INPUT WHO NEEDS INPUT? | 25 |
THE FOUNDATIONDESIGN INPUT | 27 |
THE IMPORTANCE OF DESIGN INPUT AND FDA REQUIREMENTS | 28 |
THE CONCEPT DOCUMENT | 29 |
PRODUCT PERFORMANCE SPECIFICATION | 31 |
Design Input II TO DESIGN CONTROL OR NOT TO DESIGN CONTROL | 35 |
PERFORMANCE CHARACTERISTICS | 36 |
PRODUCT CHARACTERISTICS | 42 |
MARKET REQUIREMENTS | 46 |
REGULATORY AND QUALITY ASSURANCE AND CONTRACTUAL REQUIREMENTS | 47 |
Design Outputs | 49 |
THE FDA AND DESIGN OUTPUTS | 50 |
THERE MUST BE AN END | 51 |
DESIGN OUTPUT REQUIREMENTS | 53 |
THE DEVICE MASTER RECORD | 55 |
Design Review NOT ANOTHER MEETING | 59 |
THE FDA AND DESIGN REVIEWS | 60 |
DESIGN REVIEW REQUIREMENTS | 61 |
DESIGN REVIEW FOCUS | 62 |
DESIGN REVIEW STAGES | 63 |
MEETING DYNAMICS | 66 |
Design Verification | 77 |
THE FDA AND DESIGN VERIFICATION | 78 |
TYPICAL VERIFICATION ACTIVITIES | 79 |
RISK MANAGEMENT | 80 |
HUMAN FACTORS | 85 |
RISK MANAGEMENT DOCUMENTATION | 86 |
TESTS TO DEMONSTRATE BIOCOMPATIBILITY | 111 |
Process Validation | 123 |
THE FDA AND PROCESS VALIDATION | 124 |
WHAT DO YOU CALL A GROUP OF PROCESSES? | 125 |
STATISTICAL PROCESS CONTROL | 130 |
Design Transfer | 137 |
CHECK YOUR ATTITUDE AT THE DOOR | 138 |
THE FDA AND DESIGN TRANSFER | 140 |
DESIGN TRANSFER REQUIREMENTS | 141 |
Design Changes | 143 |
THE FDA AND DESIGN CHANGES | 144 |
THE DOCUMENT CHANGE REQUEST | 146 |
The Design History File | 147 |
THE FDA AND THE DESIGN HISTORY FILE | 148 |
Questions to Expect in an Audit | 151 |
SOME QUESTIONS YOU MAY BE ASKED | 153 |
Further Reading | 157 |
Implementation Procedure | 161 |
Concept Document | 175 |
Product Specification | 179 |
Product Claims Sheet | 191 |
Risk Analysis Standard Operating Procedure | 193 |
CauseandEffects Diagram | 205 |
Validation Procedure | 209 |
Material Specification | 221 |
Quality Specification | 225 |
Design Change Procedure | 227 |
239 | |
Citi izdevumi - Skatīt visu
Design Controls for the Medical Device Industry Marie B. Teixeira,Richard Bradley Ierobežota priekšskatīšana - 2002 |
Design Controls for the Medical Device Industry Marie B. Teixeira,Richard Bradley Priekšskatījums nav pieejams - 2003 |
Bieži izmantoti vārdi un frāzes
acceptable activities actual addition and/or answer Appendix applicable appropriate approved assessment associated begin biocompatibility cause CE mark cells characteristics clinical completed components concept considered cost critical defined design control design input design outputs design review meeting determine document effective Engineering ensure equipment establish evaluation example factors Figure final function happen hazards identify important indicate initial intended labeling Level limited manufacturing materials means medical device ment methods necessary objective occur operating packaging patient performance phase possible potential probability problem procedure protocol Quality Assurance questions record regulatory request requirements responsible risk analysis safety simple specifications standard step sterilization tasks tell things tion toxicity transfer typical validation verification